American Journal of Clinical and Experimental Medicine

| Peer-Reviewed |

The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin

Received: Apr. 09, 2022    Accepted:     Published: Apr. 14, 2022
Views:       Downloads:

Share This Article

Abstract

Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, P<0.01, P<0.05 and P<0.01, respectively). (2) The level of s-HJV was 0.71±0.28ng/mL, which was obviously lower than 1.07±1.01ng/mL (t=2.6529, P<0.01) in non-anemia group. (3) There were negative correlations between BMP6 and both Hb and s-HJV (respectively r=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both <0.01), but there were no correlations between BMP6 and CRP, Hepc and SF. (4) Hepc was positively correlated with both CRP and SF (r=0.2004, t=2.0660 and r=0.3089, t=3.1045, P<0.05 and P<0.01, respectively). Hepc was negatively correlated with Hb (r=-0.2524, t=2.7525, P<0.01). Hepc had no correlation with s-HJV (P>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, P<0.01). (6) Hepc, s-HJV and SF in the normal CRP group were 5.17±3.49ug/L, 0.69±0.26ng/mL and 149.89±142.34ng/mL, respectively, which were all significantly lower than 9.02±7.14ug/L, 0.76±0.33ng/mL and 288.36±254.51ng/mL in the elevated CRP group (F=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.

DOI 10.11648/j.ajcem.20221002.13
Published in American Journal of Clinical and Experimental Medicine ( Volume 10, Issue 2, March 2022 )
Page(s) 63-66
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Tumor, Anemia, C-reactive Protein, Bone Morphogenetic Protein 6, Hepcidin

References
[1] Pan XT, Lu Y, Cheng X, et al. The expression characteristics of Serum Hepcidin and inflammatory mediator cytokine in tumor patients and their relationships with anemia [J]. Journal of Modern Laboratory Medicine, 2011, 26 (4): 22-27.
[2] Yan M, Cheng X, Lu Y, et al. The relationship of C-reactive protein levels in tumor patients with IL-6 and anemia [J]. China Continuing Medical Education, 2018, 10 (34): 88-90.
[3] Abdel-Razeq H, & Hashem H. Recent Update in the Pathogenesis and Treatment of Chemotherapy and Cancer Induced Anemia [J]. Critical Reviews in Oncology/Hematology. 2019, 145: 102837.
[4] Varga E, Pap R, Janosa G, et al. IL-6 Regulates Hepcidin Expression Via the BMP/SMAD Pathway by Altering BMP6, TMPRSS6 and TfR2 Expressions at Normal and Inflammatory Conditions in BV2 Microglia [J]. Neurochem Res. 2021, 46 (5): 1224-1238.
[5] Shi YJ, Lu Y, Wang JH, et al. Research on the expression characteristics of Neogenin and its relatedness with Hepcidin and SF in patients with tumor-associated anemia [J]. Journal of Modern Laboratory Medicine, 2016, 31 (1): 71-72.
[6] Cheng Z, Yan M, Lu Y, et al. Expression of serum BMP6 and hepcidin in cancer-related anemia [J]. Hematology. 2020, 25 (1): 134-138.
[7] Ueda N, & Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease [J]. Nutrients. 2018, 10 (9): 1173.
[8] Bloomer SA, & Brown KE. Hepcidin and Iron Metabolism in Experimental Liver Injury [J]. Am J Pathol. 2021, 191 (7): 1165-1179.
[9] Ikeda Y. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23 [J]. Kidney Int. 2021, 100 (1): 14-16.
[10] Gromadzka G, Wierzbicka D, Litwin T, et al. Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease [J]. Biometals. 2021, 34 (2): 407-414.
[11] Shan TT, Cheng Z, Yan M, et al. Analysis on expression characteristics of serum hepcidin and erythropoietin and their relationships with anemia in patients with gastric cancer [J]. Laboratory Medicine and Clinical, 2022, 19 (3): 330-332, 337.
[12] Suega K, & Widiana GR. Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease [J]. Hematol Transfus Cell Ther. 2019, 41 (4): 342-348.
[13] Senjo H, Higuchi T, Okada S, et al. Hyperferritinemia: causes and significance in a general hospital [J]. Hematology. 2018, 23 (10): 817-822.
[14] Silvestri L, Nai A, Dulja A, et al. Hepcidin and the BMP-SMAD pathway: An unexpected liaison [J]. Vitam Horm. 2019, 110: 71-99.
[15] Banerjee S, Katiyar P, Kumar L, et al. Black pepper prevents anemia of inflammation by inhibiting hepcidin over-expression through BMP6-SMAD1/ IL6-STAT3 signaling pathway [J]. Free Radic Biol Med. 2021, 168: 189-202.
[16] Xiao X, Alfaro-Magallanes VM, & Babitt JL. Bone morphogenic proteins in iron homeostasis [J]. Bone. 2020, 138: 115495.
[17] Shi YJ, & Pan XT. BMP6 and BMP4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-HJV [J]. Genet Mol Res. 2016, 15 (1): 15.
[18] Latour C, Besson-Fournier C, Gourbeyre O, et al. Deletion of BMP6 worsens the phenotype of HJV-deficient mice and attenuates hepcidin levels reached after LPS challenge [J]. Blood. 2017, 130 (21): 2339-2343.
[19] Enns CA, Ahmed R, Wang J, et al. Increased iron loading induces Bmp6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway [J]. PLoS One. 2013, 8 (4): e60534.
[20] Fillebeen C, Wilkinson N, Charlebois E, et al. Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling [J]. Blood. 2018, 132 (17): 1829-1841.
Cite This Article
  • APA Style

    Wu Yuyan, Shan Tiantian, Pan Xiangtao. (2022). The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. American Journal of Clinical and Experimental Medicine, 10(2), 63-66. https://doi.org/10.11648/j.ajcem.20221002.13

    Copy | Download

    ACS Style

    Wu Yuyan; Shan Tiantian; Pan Xiangtao. The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. Am. J. Clin. Exp. Med. 2022, 10(2), 63-66. doi: 10.11648/j.ajcem.20221002.13

    Copy | Download

    AMA Style

    Wu Yuyan, Shan Tiantian, Pan Xiangtao. The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin. Am J Clin Exp Med. 2022;10(2):63-66. doi: 10.11648/j.ajcem.20221002.13

    Copy | Download

  • @article{10.11648/j.ajcem.20221002.13,
      author = {Wu Yuyan and Shan Tiantian and Pan Xiangtao},
      title = {The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin},
      journal = {American Journal of Clinical and Experimental Medicine},
      volume = {10},
      number = {2},
      pages = {63-66},
      doi = {10.11648/j.ajcem.20221002.13},
      url = {https://doi.org/10.11648/j.ajcem.20221002.13},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ajcem.20221002.13},
      abstract = {Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, PPPt=2.6529, Pr=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both r=0.2004, t=2.0660 and r=0.3089, t=3.1045, PPr=-0.2524, t=2.7525, PP>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, PF=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Clinical Significance of the Expression of the Serum BMP 6 in the Patients with Tumor-related Anemia with Lower Levels of CRP and Hepcidin
    AU  - Wu Yuyan
    AU  - Shan Tiantian
    AU  - Pan Xiangtao
    Y1  - 2022/04/14
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ajcem.20221002.13
    DO  - 10.11648/j.ajcem.20221002.13
    T2  - American Journal of Clinical and Experimental Medicine
    JF  - American Journal of Clinical and Experimental Medicine
    JO  - American Journal of Clinical and Experimental Medicine
    SP  - 63
    EP  - 66
    PB  - Science Publishing Group
    SN  - 2330-8133
    UR  - https://doi.org/10.11648/j.ajcem.20221002.13
    AB  - Objective: To research the expression characteristic and clinical significance of the serum bone morphogenetic protein 6 (BMP6) at the lower expression condition of serum C-reactive protein (CRP) and Hepcidin (Hepc) in patients with tumor-related anemia. Methods: 113 hospitalized tumor patients from October 2019 to June 2020 and 20 healthy volunteers (control group) were recruited. We used enzyme-linked immunosorbent assay (ELISA) to determine the levels of BMP6, soluble-hemojuvelin (s-HJV) and Hepc, Electrochemiluminescence method to determine SF level, and particle-enhanced immune transmission turbidity method to determine CRP level, then analyzed their expression characteristics, correlations and clinical significance. Results: (1) The levels of BMP6, Hepc and CRP of anemia group were respectively 426.18±202.83mg/mL, 6.58±5.41ug/L and 19.10±18.24mg/L, which were all higher than 334.37±171.32mg/mL, 4.60±2.28ug/L and 3.62±3.46mg/L of non-anemia group (t=2.5804, 2.4750 and 3.4144, PPPt=2.6529, Pr=-0.2807, t=3.0812 and r=-0.2497, t=2.7230, respectively, P both r=0.2004, t=2.0660 and r=0.3089, t=3.1045, PPr=-0.2524, t=2.7525, PP>0.05). (5) The BMP6 in the normal CRP group was 461.86±142.91 mg/mL, which was significantly higher than 364.51± 129.84 mg/mL in elevated CRP group (F=11.35, PF=9.56, 4.67 and 2.84, P=0.000, 0.09, 0.046, respectively). Conclusions: When tumor patients with anemia is in a low-level condition of CRP and Hepc, the high expression of BMP6 is an important cause for the occurrence and development of anemia.
    VL  - 10
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Hematology, Taicang Hospital Affiliated to Suchow University, Taicang, China

  • Department of Hematology, Taicang Hospital Affiliated to Suchow University, Taicang, China

  • Department of Hematology, Taicang Hospital Affiliated to Suchow University, Taicang, China

  • Section